CRISPR and Vertex's two phase 1/2 studies in thalassaemia and SCD – called CLIMB-111 and CLIMB-211, respectively – have now recruited 19 patients. They are due to enrol 45 apiece, and are ...

Vertex Pharmaceuticals (NASDAQ:VRTX) announced Friday a reimbursement agreement with England’s National Health Service (NHS) ...

Financial writer recommends Crispr Therapeutics AG as a strong buy due to cash position, drug pipeline, and promising ...

Investing in stocks that aren't performing well can be a good move, but only if there are good reasons to think they will ...

Why are CRISPR companies not OK? Will Robert F. Kennedy Jr. keep his promises if he's confirmed to lead the Department of ...

Ongoing launch of CASGEVY® continues to gain momentum; new cell patient collection initiations expected to significantly grow ...

Vertex has entered a reimbursement agreement with NHS England enabling eligible SCD patients to access Casgevy in the public health system.

Vertex Pharmaceuticals Inc. (VRTX), a commercial-stage global biotechnology company, announced Friday a reimbursement agreement with ...

Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with NHS England for eligible sickle cell disease (SCD) patients to access the CRISPR/Cas9 gene-edited therapy, CASGEVY® ...

Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with NHS England for eligible sickle cell disease (SCD) patients to access the CRISPR/Cas9 gene-edited therapy ...

Ongoing launch of CASGEVY® continues to gain momentum; new cell patient collection initiations expected to significantly ...